Document:

EXHIBIT 10.15

CONFIDENTIAL
TREATMENT REQUESTED

 

CONFIDENTIAL
TREATMENT REQUESTED:  PAGES WHERE
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED ARE MARKED “CONFIDENTIAL TREATMENT
REQUESTED’’ AND APPROPRIATE SECTIONS, WHERE TEXT HAS BEEN OMITTED, ARE NOTED
WITH “[CONFIDENTIAL TREATMENT REQUESTED].’’ 
AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

 

 

ADDENDUM TO COLLABORATIVE
DEVELOPMENT AGREEMENT

SEIKAGAKU
CORPORATION - IDEC PHARMACEUTICALS CORPORATION

 

 

ADDENDUM
TO COLLABORATIVE DEVELOPMENT AGREEMENT

THIS ADDENDUM TO COLLABORATIVE DEVELOPMENT AGREEMENT
(“ADDENDUM”) is made and effective as of the 22nd day of March, 2002(“EFFECTIVE
DATE”), by and between Seikagaku Corporation organized under Japanese law and
having its principal executive offices at 1-5, Nihonbashi-honcho 2-chome,
Chuo-ku, Tokyo 103-0023, Japan  (“SK
CORPORATION”) and IDEC Pharmaceuticals Corporation, a company (originally
organized under the laws of the State of California and now organized under the
laws of the State of Delaware) and having its principal executive offices at
3030 Callan Road, San Diego, California 92121, USA (“IDEC”), with reference to
the following facts:

RECITALS

A.                                   WHEREAS,
SK CORPORATION and IDEC are parties to that certain Collaborative Development
Agreement dated December 27, 1994 (“CDA”), relating to the research and
development of antibody based products directed against the CD23 function, and
the use of such products for the potential palliation, evaluation, diagnosis
and treatment and/or prophylaxis of human disease states which are caused or
exacerbated by the CD23 determinant;

B.                                     WHEREAS,
SK CORPORATION and IDEC are also parties to that certain License Agreement
dated December 27, 1994 (“License Agreement”), providing for development and
commercialization of such products by SK CORPORATION and IDEC in their
respective territories;

C.                                     WHEREAS,
SK CORPORATION has exercised its option under the License Agreement and has
elected the SK CORPORATION TERRITORY (as defined therein);

D.                                    WHEREAS,
the CDA provides for specific preclinical testing and Phase I clinical
studies of products as set forth on Appendix B and Appendix C of the CDA and
that SK CORPORATION shall provide the development funding of such studies;

E.                                      WHEREAS, IDEC is willing to conduct additional
Phase II and Phase III clinical studies to support an application to the FDA
for marketing approval of PRODUCT and SK
CORPORATION is willing to assist in funding such clinical studies with an
intention to  obtain the clinical data and other results obtained
in the course of such clinical studies, which are useful to support an
application to the Governmental
authorities in SK CORPORATION TERRITORY for marketing approval of a
PRODUCT in the FIELD

F.                                      WHEREAS,
SK CORPORATION and IDEC, now desire to extend the CDA to provide for such
additional Phase II and Phase III clinical studies and to otherwise amend the
CDA as set forth in this ADDENDUM.

NOW, THEREFORE, in consideration of the foregoing
recitals and the mutual covenants contained herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the PARTIES hereto agree as follows:

 

2

 

AGREEMENT

1.             Definitions. All capitalized terms not otherwise
defined in this ADDENDUM shall have the meaning given them in the CDA or the License Agreement, whichever is relevant.  The following definitions shall also apply
to this ADDENDUM.

CLINICAL TRIAL shall mean
clinical study(ies) designed to support an application to the FDA for
marketing approval of a PRODUCT in
the FIELD to be conducted by IDEC in
accordance herewith, which shall comprise a part of CDA DEVELOPMENT.

CLINICAL TRIAL COSTS shall mean all costs [CONFIDENTIAL TREATMENT REQUESTED].

BLA PREPARATION COSTS shall mean those FULLY BURDENED
COSTS actually
incurred by IDEC in preparing, submitting, reviewing, or developing data or
information for the purpose of filing of any Biologics License Application
(BLA) directed to the use of PRODUCT in the FIELD including, without
limitation, FULLY BURDENED COSTS incurred in the preparation of the Integrated
Summaries and in the conduct of the Functional Activities set forth in Appendix
F.

FULLY BURDENED COSTS shall mean, with respect to a
particular item (e.g., PRODUCT, PRODUCT manufacturing, BLA PREPARATION COSTS),
the costs [CONFIDENTIAL TREATMENT REQUESTED].

2.             CDA DEVELOPMENT AND APPENDIX C.

 

(a)           The
CDA provides that the preclinical and clinical development program on a PRODUCT
within the FIELD conducted during the term of the CDA shall be carried out in
accordance with ARTICLE 3 of the CDA and APPENDIX C to the CDA.  The PARTIES desire to expand the clinical development to be carried out
under the CDA to include additional clinical studies.  To APPENDIX C to the
CDA APPENDIX C attached to this ADDENDUM shall be added.  APPENDIX C, as revised pursuant to this
ADDENDUM, is divided into two parts. 
Part I describes the preclinical and Phase I clinical development which
SK CORPORATION has funded and will continue to fund pursuant to Section 4.02 of
the CDA.  Part II describes the current
and presently anticipated future clinical development program to be managed by
IDEC, funding for which is described in paragraph 3 below.  Except as otherwise agreed to in writing by
the PARTIES, IDEC shall not have responsibility for any development activities
in the SK

 

 

3

 

CORPORATION TERRITORY.  The
Steering Committee shall retain the right to amend Appendix C when appropriate,
subject to the provisions of Section 3.03 of the CDA, as amended by this
Addendum.

 

(b)           In
partial consideration of the funding provided by SK CORPORATION, IDEC shall
consider the input of SK CORPORATION in designing CLINICAL TRIALS.  Accordingly, Section 3.02 of the CDA is
amended by adding at the end thereof the following:

 

“IDEC shall forward to SK
CORPORATION a draft clinical study protocol, which defines the designs,
population and procedures of any CLINICAL TRIAL to be conducted in accordance
with  Part 2 of Appendix C and under
which such CLINICAL TRIAL shall be operated (“PROTOCOL”), promptly after its
preparation.  SK CORPORATION shall
submit any comments or suggestions concerning the draft clinical study protocol
to IDEC within two weeks of receipt by SK CORPORATION of such draft clinical
study protocol. IDEC will consider in good faith any comments or suggestions
timely submitted  by SK CORPORATION in
accordance with this Section 3.02 as amended, however, in no circumstance shall
IDEC be required to amend a PROTOCOL to incorporate the comments or suggestions
submitted  by SK CORPORATION.

(c)           In
consideration of IDEC’s expertise in the field of clinical trial design, the
PARTIES wish to clarify IDEC’s rights with respect to business and scientific
decisions relating to development activities applicable to the IDEC TERRITORY
and hereby amend Section 3.03 of the CDA to delete the last sentence thereof
and replace same with the following provision:

 

“Notwithstanding the foregoing,
in the event the Steering Committee is unable to unanimously agree on a
decision regarding CDA DEVELOPMENT applicable to development and regulatory
approval of a Product in the IDEC TERRITORY, [CONFIDENTIAL TREATMENT REQUESTED].

(d)           It
is understood that the PARTIES require reasonable flexibility in conducting
development activities and committing their respective resources thereto.  The PARTIES desire to provide for certain
rights to discontinue the clinical studies described in Part II of Appendix C
without terminating all rights and licenses granted under Article 2 of the
License Agreement.  The PARTIES desire
to further amend Article 3 of the CDA by adding the following new Sections 3.12
and 3.13:

 

“3.12.      IDEC may elect at any time and for any reason
to discontinue CDA DEVELOPMENT relating to a CLINICAL TRIAL in the IDEC
TERRITORY.  IDEC shall give SK
CORPORATION not less than thirty (30) days written notice of its intent to
discontinue a clinical study and will use reasonable efforts

 

 

4

 

 to wind down such studies in an orderly
fashion.  Discontinuation of a CLINICAL TRIAL by IDEC pursuant to this
Section 3.12 shall not be deemed a breach of the CDA and shall not give SK
CORPORATION the right to terminate the CDA pursuant to Section 9.03 of the CDA.

3.13.        SK CORPORATION may elect to discontinue
further funding of CDA DEVELOPMENT relating to CLINICAL TRIALS in the IDEC TERRITORY
only if the election is made in writing within thirty (30) days following
(i) Steering Committee approval of a CLINICAL TRIAL in addition to those
set forth in Appendix C as amended herewith or (ii) Steering Committee
approval of a MATERIAL PROTOCOL AMENDMENT relating to a clinical study.  For purposes of this Section 3.13, “MATERIAL
PROTOCOL AMENDMENT” shall mean an increase of more than twenty-five percent
(25%) over the total patient enrollment 
currently set forth in Part 2 of Appendix C.  Notwithstanding other provisions of the CDA to the contrary, in
the event SK CORPORATION elects under Section 3.13(i) or 3.13(ii) to
discontinue funding a clinical study in the IDEC TERRITORY, SK CORPORATION
shall pay [CONFIDENTIAL
TREATMENT REQUESTED  ([CONFIDENTIAL
TREATMENT REQUESTED]) 
CLINICAL TRIAL COSTS actually incurred by IDEC up to the date of
election by SK CORPORATION to discontinue funding of such CLINICAL TRIAL, and
IDEC shall have no obligation to provide SK CORPORATION data, information or
results from any clinical study, including any applications filed with the FDA,
generated after the discontinuance of funding by SK CORPORATION.

3.             Development
Milestones and Funding.

(a)           As
of the EFFECTIVE DATE , SK CORPORATION has made certain nonrefundable payments
to IDEC pursuant to Section 4.02(a) of the CDA , and will make the unpaid
payments described in Section 4.02(a) upon completion of the applicable
milestones.

(b)           In
order to clarify what shall be deemed “completion of Phase I testing,” for
purposes of Section 4.02(a) of the CDA and Section 3(a) of this Addendum, the
PARTIES agree that:  (i) Phase I testing
of the PRODUCT in the U.S. shall be deemed completed when that certain study
identified as “Trial 152-02” and described in Part I of APPENDIX C of the CDA
(as amended) is completed or as may be otherwise agreed to by the PARTIES, and
(ii) Phase I testing of the PRODUCT in Europe shall be deemed completed
upon the commencement of a Phase II trial in Europe even if such Phase II trial
commences prior to completion of a Phase I trial in Europe and even if a Phase
I trial was never initiated.

(c)           The
PARTIES also desire to set forth their agreement regarding the funding of
further CDA DEVELOPMENT.  ARTICLE 4 of
the CDA is hereby amended to include the following new Sections 4.04 - 4.07
with respect to funding of CDA DEVELOPMENT described in Part II of APPENDIX C
(as amended):

 

 

5

 

 

“4.4.  SK
CORPORATION shall make payment to IDEC for [CONFIDENTIAL TREATMENT REQUESTED] ([CONFIDENTIAL
TREATMENT REQUESTED]) of 
CLINICAL TRIAL COSTS  in accordance
with Section 4.07.

4.05.  SK
CORPORATION shall reimburse IDEC for [CONFIDENTIAL TREATMENT REQUESTED] ([CONFIDENTIAL
TREATMENT REQUESTED]) of BLA PREPARATION COSTS in accordance with
Section 4.07.

4.06. SK CORPORATION shall reimburse IDEC for [CONFIDENTIAL
TREATMENT REQUESTED] ([CONFIDENTIAL TREATMENT REQUESTED]) of
FULLY BURDENED COSTS for the manufacture of PRODUCT and/or or costs incurred by
IDEC for manufacture by a THIRD PARTY of PRODUCT (MANUFACTURING COSTS) to be
used in conducting clinical trials designed to support approval by the FDA for
use of PRODUCT in the FIELD.  Such
reimbursement shall be made at the end of each manufacturing campaign for
PRODUCT and in accordance with Section 4.07. 
Included in MANUFACTURING COSTS are [CONFIDENTIAL TREATMENT REQUESTED]. In the
event that IDEC determines that a portion of PRODUCT from a manufacturing
campaign is not to be used for conducting clinical trials in the FIELD (UNUSED
PORTION), IDEC shall, within a reasonable period of time after making such
determination, reimburse SK CORPORATION for the pro rata share of the
MANUFACTURING COSTS associated with such UNUSED PORTION.

4.07.  For each payment by SK CORPORATION in accordance with Section 4.04, 4.05 or
4.06, IDEC shall issue an invoice covering the amount payable by SK CORPORATION
hereunder for the activities or payment made by IDEC during each calendar
quarter  and furnish it to SK CORORATION
by the last day of the next calendar quarter, together with invoices or other
evidence which reasonably prove IDEC’s payment or costs.  Within thirty (30) days after its receipt of
each invoice hereunder, SK CORPORATION shall make relevant payments to IDEC.

(d)           The
amounts payable under new Sections 4.04 — 4.06of the CDA, as amended hereby are
in addition to the amounts payable under Section 4.02(a) of the CDA.

 

4.             Trademarks
and Tradenames, etc.  The CDA does
not provide for the selection and registration of trademarks for PRODUCT
developed pursuant to the CDA.  The
PARTIES desire that the PRODUCT be sold in the TERRITORY under a single
worldwide trademark, if possible. 
Article 5 of the CDA is hereby amended to add the following new sections
5.09 and 5.10:

5.09.  The
Steering Committee shall use its BEST EFFORTS to select a worldwide trademark
for both the SK CORPORATION TERRITORY and the IDEC TERRITORY.  If the PARTIES cannot agree on a worldwide
trademark 

 

 

6

 

(COMMON
TRADEMARK), PRODUCT shall be sold in the IDEC TERRITORY under trademarks
selected and owned by IDEC and SK CORPORATION may select a different trademark
for use in the SK CORPORATION TERRITORY, which trademark shall be subject to
the reasonable approval of IDEC.  IDEC
shall control the preparation, prosecution and maintenance of all applications
related to such COMMON TRADEMARK.  IDEC
shall bear the cost in the IDEC TERRITORY and SK CORPORATION shall reimburse
IDEC for the costs incurred in the SK CORPORATION TERRITORY.  IDEC shall be the registered owner of the
trademark and hereby grants SK CORPORATION an exclusive license to use such
COMMON TRADEMARK in the SK CORPORATION TERRITORY for the purpose of promoting,
marketing and selling PRODUCTS and SK CORPORATION shall have the right to grant
sublicenses to use such COMMON TRADEMARK only in connection with the grant of
sublicenses permitted under the License Agreement.  Until a worldwide trademark is selected, the PARTIES shall use
the designation “IDEC-152” in any announcement, disclosure, publication, or
presentation relating to this CDA or otherwise related to the development of
PRODUCT.  SK may use its own designation
in any such announcement, disclosure, publication, or presentation relating to
this CDA or otherwise related to the development of PRODUCT, so long as the
designation “IDEC-152” is also used with equal prominence at each occurrence of
SK’s chosen designation.

 

5.10.  IDEC agrees to keep SK CORPORATION advised
of the progress of and the data obtained from CLINICAL TRIAL in a timely manner
from time to time during the term of the CDA. 
To enable such smooth disclosure, IDEC shall provide SK CORPORATION with
a monthly report of the progress of CLINICAL TRIAL and the PARTIES shall hold
semi-annual meetings.  The places and
other details of such meetings shall be determined separately.

                5.             Rights and Duties Upon
Termination. Section 10.02 shall be deleted and replaced as follows:

 

10.02 Termination of this
CDA shall terminate all rights and further obligations between the PARTIES
arising from this CDA, except:

(a)           the payment obligations set forth in
Section 4.02(a)4 for Completion of Phase I testing of PRODUCT in the U.S.;

(b)           Sections 3.13, 4.04, 4.05, 4.06 and
4.07 to the extent CLINICAL TRIAL COSTS, BLA PREPARATION COSTS or MANUFACTURING
COSTS are actually incurred by IDEC up to the date of termination of this CDA;

(c)           those rights and obligations
described in Section 5.07 for data or other information generated or provided
by either PARTY during the term of this CDA; and

 

 

7

 

 

(d)           Sections 5.03, 5.05, 5.08, 10.01,
10.02, 10.04 and Articles 11 and 13 through 19 and except existing rights
against the other PARTY for a breach by that PARTY.

6.  No
Further Modification.  Except as specifically set forth in this ADDENDUM,
all of the terms and provisions of the CDA shall remain in full force and
effect and all references to the CDA shall refer to the CDA as amended by this
ADDENDUM.

IN WITNESS WHEREOF, the
PARTIES, through their authorized officers, have executed this ADDENDUM.

	
  SEIKAGAKU
  CORPORATION

  
	
   

  	
   

  
	
  By:

  	
  /s/ Shirow Enoki

  
	
   

  	
   

  
	
  Title:

  	
  President

  
	
   

  	
   

  
	
  Date:

  	
  3/22/2002

  
	
   

  
	
  IDEC
  PHARMACEUTICALS CORPORATION

  
	
   

  	
   

  
	
  By:

  	
  /s/ William Rohn

  
	
   

  	
   

  
	
  Title:

  	
  President and Chief Operating Officer

  
	
   

  	
   

  
	
  Date:

  	
  3/8/02

  

 

 

8QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.01  

 
 

FIRST AMENDMENT TO 364-DAY CREDIT AGREEMENT    
  

        THIS FIRST AMENDMENT TO 364-DAY CREDIT AGREEMENT (this
"Amendment"), dated as of March 29, 2002, is entered into among WELLPOINT HEALTH
NETWORKS INC., a Delaware corporation (the "Borrower"), the Lenders identified on the signature pages hereto (the
"Lenders"), BANK OF AMERICA, N.A., as administrative agent for the Lenders (in such capacity, the
"Administrative Agent") and JPMORGAN, a division of Chase Securities Inc., as syndication agent
(in such capacity, the "Syndication Agent"). Terms used but not otherwise defined herein shall have the meanings provided in the Credit Agreement
described below. 

W I T N E S S E T H  

        WHEREAS, the Borrower, the Lenders, the Administrative Agent and the Syndication Agent entered into that certain
Credit Agreement dated as of March 30, 2001 (the "Existing Credit Agreement"); and 

        WHEREAS, the Borrower has requested to extend the Commitment Termination Date for an additional 364 day period, and certain Lenders
party to the Existing Credit Agreement have agreed to extend their respective Commitments and amend the Existing Credit Agreement in accordance with such request and as provided herein. 

        NOW, THEREFORE, in consideration of the agreements hereinafter set forth, and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the parties hereto agree as follows: 

PART 1

DEFINITIONS  

        SUBPART 1.1    Certain Definitions.    Unless otherwise defined herein
or the context otherwise requires, the following terms used in this Amendment, including its preamble and recitals, have the following meanings: 

        "Amended Credit Agreement" means the Existing Credit Agreement as amended hereby. 

        "Amendment No. 1 Effective Date" is defined in Subpart 3.1. 

        SUBPART 1.2    Other Definitions.    Unless otherwise defined herein
or the context otherwise requires, terms used in this Amendment, including its preamble and recitals, have the meanings provided in the Existing Credit Agreement. 

PART 2

AMENDMENTS TO EXISTING CREDIT AGREEMENT  

        Effective on (and subject to the occurrence of) the Amendment No. 1 Effective Date, the Existing Credit Agreement is hereby amended in accordance with this  Part 2. 

        SUBPART 2.1    Amendments to
Section 1.01.    Section 1.01 of the Credit Agreement is hereby amended in the following respects: 

        (a)  The
definition of "Commitment Termination Date" is hereby amended in its entirety to read as follows: 

        "Commitment Termination Date" shall mean the date 364 days following March 29, 2002. 

        (b)  The
definition of "Maturity Date" is hereby amended in its entirety to read as follows: 

        "Maturity Date" shall mean the date 364 days following the Commitment Termination Date. 

        SUBPART 2.2    Amendments to Schedule 2.01.    Schedule 2.01  of the Existing Credit Agreement is hereby replaced with Schedule 2.01 attached hereto. 

PART 3

CONDITIONS TO EFFECTIVENESS  

        SUBPART 3.1    Amendment No. 1 Effective Date 1.    This
Amendment shall be and become effective as of the date hereof (the "Amendment No. 1 Effective Date") when all of the conditions set forth in this  Part III
shall have been satisfied, and thereafter this Amendment shall be known, and may be referred to, as the
"Amendment". 

        SUBPART 3.2    Execution of Counterparts of Amendment.    The
Administrative Agent shall have received counterparts (or other evidence of execution, including telephonic message, satisfactory to the Administrative Agent) of this Amendment, which collectively
shall have been duly executed on behalf of each of the Borrower, the Lenders, the Administrative Agent and the Syndication Agent. 

        SUBPART 3.4    Fees and Expenses.    The Borrower has paid all fees
and expenses incurred in connection with the negotiation, preparation, execution and delivery of this Amendment and the other transactions contemplated herein including, without limitation, the legal
fees and expenses of Moore & Van Allen, counsel to the Administrative Agent. 

        SUBPART 3.5    Other Items.    The Administrative Agent shall have
received such other documents, agreements or information which may be reasonably requested by the Administrative Agent. 

PART 4

MISCELLANEOUS  

        SUBPART 4.1    Representations and Warranties.    Each of the Borrower
and the Guarantors hereby represents and warrants to the Administrative Agent and the Lenders that, after giving effect to this Amendment, (a) no Default or Event of Default exists under the
Credit Agreement and (b) the representations and warranties set forth in Section 3 of the Existing Credit Agreement are, subject to
the limitations set forth therein, true and correct in all material respects as of the date hereof (except for those which expressly relate to an earlier date). 

        SUBPART 4.2    Reaffirmation of obligations.    The Borrower hereby
ratifies the Credit Agreement and acknowledges and reaffirms (a) that it is bound by all terms of the Credit Agreement applicable to it and (b) that it is responsible for the observance
and full performance of its respective obligations under the Credit Agreement. 

        SUBPART 4.3    Cross-References.    References in this Amendment to
any Part or Subpart are, unless otherwise specified, to such Part or Subpart of this Amendment. 

        SUBPART 4.4    Instrument Pursuant to Existing Credit
Agreement.    This Amendment is executed pursuant to the Existing Credit Agreement and shall (unless otherwise expressly indicated therein) be construed, administered
and applied in accordance with the terms and provisions of the Existing Credit Agreement. 

        SUBPART 4.5    References in Other Credit Documents.    At such time
as this Amendment shall become effective pursuant to the terms of Subpart 3.1, all references to the "Credit Agreement" shall be deemed to refer to the
Credit Agreement as amended by this Amendment. 

        SUBPART 4.6    Counterparts/Telecopy.    This Amendment may be
executed by the parties hereto in several counterparts, each of which shall be deemed to be an original and all of which shall constitute together but one and the same agreement. Delivery of executed
counterparts of the Amendment by telecopy shall be effective as an original and shall constitute a representation that an original shall be delivered. 

        SUBPART 4.7    Governing Law.    THIS AMENDMENT SHALL BE DEEMED TO BE
A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW, BUT EXCLUDING
ALL OTHER CHOICE OF LAW AND CONFLICTS OF LAW RULES). 

        SUBPART 4.8    Successors and Assigns.    This Amendment shall be
binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. 

        SUBPART 4.9    General.    Except as amended hereby, the Existing
Credit Agreement and all other Credit Documents shall continue in full force and effect. 

[Remainder
of Page Intentionally Left Blank] 

        IN WITNESS WHEREOF, the parties hereto have executed this Amendment to Credit Agreement as of the date first above written. 

	BORROWER:	WELLPOINT HEALTH NETWORKS INC.,
 a Delaware corporation	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/  R. DAVID KRETSCHMER      	 
	 	 	
	 
	 	Name:	R. David Kretschmer
	 
	 	Title:	V.P., Treasurer
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	ADMINISTRATIVE AGENT:	BANK OF AMERICA, N.A.
	 	 	 	 
	 	 	 	 
	 	By:	/s/  JOSEPH L. CORAH      	 
	 	 	
	 
	 	Name:	Joseph L. Corah
	 
	 	Title:	Principal
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	SYNDICATION AGENT:	JPMORGAN,
 a division of Chase Securities, Inc.
	 	 	 	 
	 	 	 	 
	 	By:	/s/  ANDREW BRODE      	 
	 	 	
	 
	 	Name:	Andrew Brode
	 
	 	Title:	Vice President
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	LENDERS:	BANK OF AMERICA, N.A.
	 	 	 	 
	 	 	 	 
	 	By:	/s/  JOSEPH L. CORAH      	 
	 	 	
	 
	 	Name:	Joseph L. Corah
	 
	 	Title:	Principal
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	THE INDUSTRIAL BANK OF JAPAN, LIMITED
	 	 	 	 
	 	 	 	 
	 	By:	/s/  VICENTE L. TIMIRAOS      	 
	 	 	
	 
	 	Name:	Vicente L. Timiraos
	 
	 	Title:	Joint General Manager
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	BANK ONE, N.A.
	 	 	 	 
	 	 	 	 
	 	By:	/s/  VINCENT K. KELLY      	 
	 	 	
	 
	 	Name:	Vincent K. Kelly
	 
	 	Title:	Managing Director
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	JP MORGAN CHASE BANK
	 	 	 	 
	 	 	 	 
	 	By:	/s/  DAWN LEE LUM      	 
	 	 	
	 
	 	Name:	Dawn Lee Lum
	 
	 	Title:	Vice President
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	CITICORP USA, INC.
	 	 	 	 
	 	 	 	 
	 	By:	/s/  STEPHEN P. ZWICK      	 
	 	 	
	 
	 	Name:	Stephen P. Zwick
	 
	 	Title:	VP
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	MELLON BANK, N.A.
	 	 	 	 
	 	 	 	 
	 	By:	/s/  MARSHA WICKER      	 
	 	 	
	 
	 	Name:	Marsha Wicker
	 
	 	Title:	VP
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	CREDIT SUISSE FIRST BOSTON, CAYMAN ISLANDS BRANCH
	 	 	 	 
	 	 	 	 
	 	By:	/s/  WILLIAM S. LUTKINS      	 
	 	 	
	 
	 	Name:	William S. Lutkins
	 
	 	Title:	Director
	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/  ROBERT N. FINNEY      	 
	 	 	
	 
	 	Name:	Robert N. Finney
	 
	 	Title:	Managing Director
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	THE BANK OF NEW YORK
	 	 	 	 
	 	 	 	 
	 	By:	/s/  REBECCA K. LEVINE      	 
	 	 	
	 
	 	Name:	Rebecca K. Levine
	 
	 	Title:	Vice President
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	SUNTRUST BANK
	 	 	 	 
	 	 	 	 
	 	By:	/s/  W. BROOKS HUBBARD      	 
	 	 	
	 
	 	Name:	W. Brooks Hubbard
	 
	 	Title:	Vice President
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	UBS AG, STAMFORD BRANCH
	 	 	 	 
	 	 	 	 
	 	By:	/s/  WILFRED V. SAINT      	 
	 	 	
	 
	 	Name:	Wilfred V. Saint
	 
	 	Title:	Associate Director
	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/  JUAN ZUNIGA      	 
	 	 	
	 
	 	Name:	Juan Zuniga
	 
	 	Title:	Associate Director
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	DEUTSCHE BANK AG

New York and/or Cayman Islands Branches
	 	 	 	 
	 	 	 	 
	 	By:	/s/  SCOTTYE D. LINDSEY      	 
	 	 	
	 
	 	Name:	Scottye D. Lindsey
	 
	 	Title:	Vice President
	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/  MARGUERITE SUTTON      	 
	 	 	
	 
	 	Name:	Marguerite Sutton
	 
	 	Title:	Vice President
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	LEHMAN COMMERCIAL PAPER INC.
	 	 	 	 
	 	 	 	 
	 	By:	/s/  FRANCIS J. CHANG      	 
	 	 	
	 
	 	Name:	Francis J. Chang
	 
	 	Title:	Vice President
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	WACHOVIA BANK, N.A.
	 	 	 	 
	 	 	 	 
	 	By:	/s/  DANIEL J. NORTON      	 
	 	 	
	 
	 	Name:	Daniel J. Norton
	 
	 	Title:	Director
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	KBC BANK, N.V.
	 	 	 	 
	 	 	 	 
	 	By:	/s/  ROBERT SNAUFFER      	 
	 	 	
	 
	 	Name:	Robert Snauffer
	 
	 	Title:	First Vice President
	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/  RAYMOND F. MURRAY      	 
	 	 	
	 
	 	Name:	Raymond F. Murray
	 
	 	Title:	First Vice President
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	FLEET NATIONAL BANK
	 	 	 	 
	 	 	 	 
	 	By:	/s/  GORDON B. COUGHLIN      	 
	 	 	
	 
	 	Name:	Gordon B. Coughlin
	 
	 	Title:	Vice President
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	BNP PARIBAS
	 	 	 	 
	 	 	 	 
	 	By:	/s/  C. BETTLES      	 
	 	 	
	 
	 	Name:	C. Bettles
	 
	 	Title:	Managing Director
	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/  JANICE S.H. HO      	 
	 	 	
	 
	 	Name:	Janice S. H. Ho
	 
	 	Title:	Director
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	THE SUMITOMO BANK, LIMITED
	 	 	 	 
	 	 	 	 
	 	By:	/s/  AL GALLUZZO      	 
	 	 	
	 
	 	Name:	Al Galluzzo
	 
	 	Title:	Senior Vice President
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	SOCIETE GENERALE
	 	 	 	 
	 	 	 	 
	 	By:	/s/  RICHARD BERNAL      	 
	 	 	
	 
	 	Name:	Richard Bernal
	 
	 	Title:	Director, Corporate Banking
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	CREDIT LYONNAIS NEW YORK BRANCH
	 	 	 	 
	 	 	 	 
	 	By:	/s/  BERNARD WEYMULLER      	 
	 	 	
	 
	 	Name:	Bernard Weymuller
	 
	 	Title:	Senior Vice President
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

	 	BANCA DI ROMA
	 	 	 	 
	 	 	 	 
	 	By:	/s/  LUCA BALESTRA      	 
	 	 	
	 
	 	Name:	Luca Balestra (#25050)
	 
	 	Title:	Senior Vice President and Manager
	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/  RICHARD G. DIETZ      	 
	 	 	
	 
	 	Name:	Richard G. Dietz (#97271)
	 
	 	Title:	Vice President
	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	[signature pages continue]

SCHEDULE 2.01

COMMITMENTS

(364-Day Credit Agreement)  

	Lender
 
	 	Commitment Amount
	 	Commitment Percentage
	 
	Bank of America, N.A.	 	$	20,625,000	 	8.250000000	%
	The Chase Manhattan Bank	 	$	20,625,000	 	8.250000000	%
	The Industrial Bank of Japan, Limited	 	$	15,000,000	 	6.000000000	%
	Bank One, N.A.	 	$	15,000,000	 	6.000000000	%
	Citicorp USA, Inc.	 	$	15,000,000	 	6.000000000	%
	Mellon Bank, N.A.	 	$	12,500,000	 	5.000000000	%
	Credit Suisse First Boston	 	$	12,500,000	 	5.000000000	%
	The Bank of New York	 	$	12,500,000	 	5.000000000	%
	SunTrust Bank	 	$	12,500,000	 	5.000000000	%
	UBS AG, Stamford Branch	 	$	12,500,000	 	5.000000000	%
	Deutsche Bank AG	 	$	12,500,000	 	5.000000000	%
	Lehman Commercial Paper Inc.	 	$	12,500,000	 	5.000000000	%
	Wachovia Bank, N.A.	 	$	12,500,000	 	5.000000000	%
	KBC Bank, N.V.	 	$	12,500,000	 	5.000000000	%
	Fleet National Bank	 	$	10,625,000	 	4.250000000	%
	BNP Paribas	 	$	10,625,000	 	4.250000000	%
	The Sumitomo Bank, Limited	 	$	8,750,000	 	3.500000000	%
	Societe Generale	 	$	8,750,000	 	3.500000000	%
	Credit Lyonnais New York Branch	 	$	6,250,000	 	2.500000000	%
	Banca Di Roma	 	$	6,250,000	 	2.500000000	%
	 	 	
	 	
	 
	Total:	 	$	250,000,000.00	 	100.000000000	%

QuickLinks

FIRST AMENDMENT TO 364-DAY CREDIT AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00039-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00039-of-00352.parquet"}]]